JP2022520107A5 - - Google Patents
Info
- Publication number
- JP2022520107A5 JP2022520107A5 JP2021547420A JP2021547420A JP2022520107A5 JP 2022520107 A5 JP2022520107 A5 JP 2022520107A5 JP 2021547420 A JP2021547420 A JP 2021547420A JP 2021547420 A JP2021547420 A JP 2021547420A JP 2022520107 A5 JP2022520107 A5 JP 2022520107A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025051765A JP2025092553A (ja) | 2019-02-14 | 2025-03-26 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805350P | 2019-02-14 | 2019-02-14 | |
| US62/805,350 | 2019-02-14 | ||
| US201962814935P | 2019-03-07 | 2019-03-07 | |
| US62/814,935 | 2019-03-07 | ||
| PCT/US2020/018113 WO2020168079A1 (en) | 2019-02-14 | 2020-02-13 | Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051765A Division JP2025092553A (ja) | 2019-02-14 | 2025-03-26 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022520107A JP2022520107A (ja) | 2022-03-28 |
| JP2022520107A5 true JP2022520107A5 (https=) | 2023-02-20 |
| JPWO2020168079A5 JPWO2020168079A5 (https=) | 2023-02-20 |
Family
ID=69954108
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547420A Withdrawn JP2022520107A (ja) | 2019-02-14 | 2020-02-13 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
| JP2025051765A Pending JP2025092553A (ja) | 2019-02-14 | 2025-03-26 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051765A Pending JP2025092553A (ja) | 2019-02-14 | 2025-03-26 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200331993A1 (https=) |
| EP (1) | EP3924380A1 (https=) |
| JP (2) | JP2022520107A (https=) |
| KR (1) | KR20210126045A (https=) |
| CN (2) | CN119326881A (https=) |
| AU (1) | AU2020223298A1 (https=) |
| CA (1) | CA3130300A1 (https=) |
| MX (1) | MX2021009789A (https=) |
| WO (1) | WO2020168079A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| US20220059221A1 (en) * | 2020-08-24 | 2022-02-24 | Nvidia Corporation | Machine-learning techniques for oxygen therapy prediction using medical imaging data and clinical metadata |
| KR20230134533A (ko) * | 2021-01-22 | 2023-09-21 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항-c5 항체를 이용한 보체 매개 혈전성 미세혈관병증의치료 방법 |
| JP2024526742A (ja) * | 2021-07-14 | 2024-07-19 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 重症筋無力症の治療のための抗ｃ５抗体の投与量及び投与 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| US20160168237A1 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| JP2019517473A (ja) * | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| ES2984352T3 (es) | 2016-06-14 | 2024-10-29 | Regeneron Pharma | Anticuerpos anti-C5 y usos de los mismos |
| SI3658184T1 (sl) * | 2017-07-27 | 2024-01-31 | Alexion Pharmaceuticals, Inc., | Formulacije z visoko koncentracijo protiteles proti-C5 |
| CA3080187A1 (en) * | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
-
2020
- 2020-02-13 MX MX2021009789A patent/MX2021009789A/es unknown
- 2020-02-13 CA CA3130300A patent/CA3130300A1/en active Pending
- 2020-02-13 EP EP20713785.2A patent/EP3924380A1/en active Pending
- 2020-02-13 CN CN202411307488.2A patent/CN119326881A/zh active Pending
- 2020-02-13 KR KR1020217028172A patent/KR20210126045A/ko not_active Ceased
- 2020-02-13 CN CN202080021230.XA patent/CN113614106A/zh active Pending
- 2020-02-13 JP JP2021547420A patent/JP2022520107A/ja not_active Withdrawn
- 2020-02-13 WO PCT/US2020/018113 patent/WO2020168079A1/en not_active Ceased
- 2020-02-13 AU AU2020223298A patent/AU2020223298A1/en active Pending
- 2020-02-14 US US16/791,415 patent/US20200331993A1/en not_active Abandoned
-
2024
- 2024-10-31 US US18/933,215 patent/US20250243264A1/en active Pending
-
2025
- 2025-03-26 JP JP2025051765A patent/JP2025092553A/ja active Pending